Correlación de PET/TC con FDG temprana y ADNtc en pacientes con melanoma tratados con inhibidores de puntos de control inmunitario (ICI)
Correlación entre la tomografía por emisión de positrones/tomografía computarizada (PET/CT) de intervalo temprano con 18F-fluorodesoxiglucosa y el ADN tumoral circulante (ctDNA) en pacientes con melanoma avanzado tratados con inhibidores de puntos de control inmunológico
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a pilot, prospective, observational study to estimate the degree to which baseline and early interval 18F-FDG PET/CT imaging within 3-4 weeks of ICI therapy initiation can accurately correlate with ctDNA level trends, predict clinical response, onset of immune-related adverse events, and survival outcomes in advanced stage melanoma patients.
Primary Objective
• To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks correlates with ctDNA level changes in advanced melanoma patients.
Secondary Objectives
- To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks predicts clinical efficacy at standard disease assessment time points in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT predicts development of clinical irAEs in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts progression-free survival (PFS) in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts overall survival (OS) in advanced melanoma patients.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Hospitals and Clinics (UWHC)
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
24 participants with advanced stage III or stage IV melanoma with measurable disease who are deemed appropriate for treatment with ICI therapy.
Descripción
Inclusion Criteria:
- Willing to provide informed consent.
- Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned.
- Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy.
- Individuals at least 18 years of age.
- Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.
- Willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria:
- Not able to receive treatment with ICI therapy
- Use of investigational drugs, biologics, or devices within 30 days prior to enrollment.
- Women who are pregnant, lactating, or planning on becoming pregnant during the study.
- Not suitable for study participation due to other reasons at the discretion of the investigators.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Pacientes con melanoma avanzado con inhibidores de puntos de control inmunológico
|
research scan 3-4 weeks after start of immunotherapy
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in ctDNA level from baseline to 3-4 week after the start of therapy
Periodo de tiempo: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
ctDNA level is monitored per standard of care in this population, data from chart review. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Periodo de tiempo: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy reported as SUV max. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Correlation between ctDNA level change and 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Periodo de tiempo: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy with quantitative changes in ctDNA levels at baseline and at 3-4 weeks after starting ICI therapy. Pearson's or Rank's correlation coefficient will be used to measure the baseline measures for ctDNA level trends and PET/CT responses and for those measurements at 3-4 weeks. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Diagnostic Accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition as measured by Area under the Curve
Periodo de tiempo: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Receiver-operator curve analysis will be performed to determine the diagnostic accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition (area under the curve). |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate (ORR)
Periodo de tiempo: up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. ORR is Partial Response (PR) plus Complete Response (CR). |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Disease Control Rate (DCR)
Periodo de tiempo: up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. DCR is Stable Disease (SD) plus PR plus CR. |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Change in Standard Uptake Value (SUV) metrics with onset of Immune Related Adverse Events (irAE)
Periodo de tiempo: up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate organ-level FDG uptake and changes from the baseline and early 18F-FDG PET/CT assessment with onset of first, second, and third symptomatic irAE per CTCAE v5.0 |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Progression Free Survival (PFS)
Periodo de tiempo: up to 3 years after the first ICI dose (approximately 3 years on study)
|
PFS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and PFS
Periodo de tiempo: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT treatment response with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and PFS
Periodo de tiempo: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Overall Survival (OS)
Periodo de tiempo: up to 3 years after the first ICI dose (approximately 3 years on study)
|
OS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and OS
Periodo de tiempo: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT response assessment with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and OS
Periodo de tiempo: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Vincent Ma, MD, University of Wisconsin, Madison
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Enfermedades de la piel
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Nevos y Melanomas
- Neoplasias De La Piel
- Enfermedades de la piel y del tejido conectivo
- Melanoma
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Tomografía
- Imágenes de diagnóstico
- Radiografía
- Interpretación de imágenes, asistida por computadora
- Mejora de la imagen radiográfica
- Mejora de la imagen
- Fotografía
- Tomografía, rayos X
- Tomografía, rayos X calculados
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2023-1089
- A534260 (Otro identificador: UW Madison)
- UW23077 (Otro identificador: UWCCC)
- Protocol Version 2/12/2024 (Otro identificador: UW Madison)
- NCI-2023-11059 (Identificador de registro: NCI Trial ID)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .